Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-516-1 | CAS number: 141-97-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The test item EAA was tested in two subacute oral toxicity studies over 28 days. Treatment was either by gavage or feeding. Both studies were performed under GLP
having a Klimisch 1 rating. Dose levels were 0, 50, 225 and 1000 mg/kg/day in the gavage study and 0, 100, 300 and 1000 mg/kg/day in the feeding test. In the gavage test, 5 animals per sex and dose group were treated with the test article. In addition, another 5 animals per sex of the control and highest dose group were treated and further observed in a 2-weeks recovery period. For the feeding study, 16 males and 16 females were tested per dose group, without treatment-free recovery period. There were no toxicologically relevant findings observed in both studies. Results were comparable, in both studies the NOEL/NOAEL values were found to be 1000 mg/kg/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- February 1990 - April 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- - Batch-no.: 157
- Storage: room temperature - Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- the rodent species is acceptable to the regulatory authorities and has documented susceptibility to a wide range of toxic substances. Background data of the strain are available at the testing facility. There are no known contra-indications to its use.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: IFFA Credo, L'Arbresle, France
- Age at study initiation: 6 weeks
- Weight at study initiation: males 172-197.9 g / females 141.5-174.2 g
- Housing: gang housing (groups of 5 animals)
- Acclimation period: 7 days - Route of administration:
- oral: gavage
- Details on route of administration:
- ROUTE AND METHOD OF ADMINISTRATION
- Route: oral
- Justification of the route: potential human exposure is by the oral route
- Volume of administration: 10 ml/kg/day
- Individual dose volumes were calculated weekly using the most recent body weight
- Method of administration: gavage, using a metal cannula - Vehicle:
- water
- Remarks:
- distilled
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
- Solution of the test article in the vehicle at the concentrations of 5, 22.5 and 100 mg/ml
- Stabilify of the test article in the vehicle: determined over 24 hours for the lowest and highest concentrations. The analyses were carried out at test lab
- Frequency of preparation: daily
- Storage: at room temperature, protected from light
- Analysis of formulation: a sample from each preparation (including control group) was taken at weeks 1 and 4 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability/homogeinity was determined for the lowest and highest dose concentrations by Gas chromatography (GC):
- Apparatus: Varian 3400 with autosampler
- Detector: FID
- Column: OV101, 15 m x 0.53 mm
- Injection volume: 1 ul
- Gas: nitrogen 10 ml/min
- Temperature: injector: 210°C / detector 260°C / column oven 70°C
- Test sample: dosing solutions were dissolved in acetone
The test item was found to be stable at room temperature over 24 hours. - Duration of treatment / exposure:
- Duration:
- males and females killed at week 4 : 29 days
- males and females killed at week 6 : 28 days
For animals killed at week 4, treatment continued until the day before necropsy. - Frequency of treatment:
- Once daily
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 225 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 60 animals were used in this study:
- 0 mg/kg/day: 20 (5 males/5 females for treatment period PLUS 5 males/5 females for recovery period)
- 50 mg/kg/day: 10 (5 males/5 females)
- 225 mg/kg/day: 10 (5 males/5 females)
- 1000 mg/kg/day: 20 (5 males/5 females for treatment period PLUS 5 males/5 females for recovery period) - Control animals:
- yes
- Details on study design:
- Dose selection rationale:
The high dose level of 1000 mg/kg/day is the maximal dose recommended by the OECD and EEC guidelines. The low dose level is expected to be a noobservable effect level and the intermediate dose level of 225 mg/kg is close to the geometric mean between the low and high dose levels. - Positive control:
- no positive control tested
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Animals were observed daily, before and at least once after dosing, Full clinical observation was performed weekly.
BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were recorded weekly
FOOD CONSUMPTION:
- Food consumption was measured weekly for each cage from the first week of treatment
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Once pretest and at week 4
- Examination: All animals; Direct and indirect ophthalmoscopy, a mydriatic agent (tropicamidel was instilled in to the eyes before examination
HAEMATOLOGY/CLINICAL CHEMISTRY: Yes
- Animals examined and frequency : 5 animals for each sex/group at week 4
- Samples: blood was withdrawn from the retro-orbital sinus following light ether anaesthesia on overnight fasted animals (about 16 hours). Bone marrow smears were prepared at scheduled necropsy for all animals killed at week 4. In consideration of the results for other parameters examined during the study.
URINALYSIS: Yes
- Collected in metabolism cages (approximately 16 hours) from animals deprived of food and water but receiving 20 ml/kg of mains water by gavage before being placed in the metabolism cages
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
At weeks 4 and 6, the animals were necropsied after randomisation. The animals were weighed before necropsy. The animals were killed by carbon dioxide inhalation and exsanguination. All animals were submitted to full necropsy procedures including examination of :
- the external surface
- ail orifices
- the cranial cavity
- the carcass
- the external surface of the brain and of samples of the spinal cord
- the thoracic, abdominal and pelvic cavities and viscera
- the cervical tissues and organs
HISTOPATHOLOGY: Yes
All organs/tissues sampled were fixed and preserved in 10% neutral formalin with the following exception: bone marrow smears fixed in methanol. All sections were stained with haematoxylin and eosin.
Histopathological examinations were performed on all organs/tissues. For all animals in groups 1 (control) and 4 (high dose) at week 4. In each group, histopathological examination was performed for all gross lesions except those for which the diagnosis was judged unnecessary for the outcome of the study by the pathologist. - Other examinations:
- none
- Statistics:
- no data
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- In week 2, approximately half the high dose animals (group 4) were salivating immediately after dosing. In weeks 3 and 4, this observation was present in all high dose animals. Salivation is seen occasionally in studies of this type (gavage) and probably represents a local reaction to the test article. It is considered not to represent systemic toxicity.
- Mortality:
- no mortality observed
- Description (incidence):
- There were no deaths.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no biologically significant differences between the groups in the amount of body weight gained.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The differences in food consumption between the groups were small and not considered to be treatment-related. Food conversion ratios were similar in all groups.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- No treatment-related effects observed.
- Water consumption and compound intake (if drinking water study):
- not specified
- Description (incidence and severity):
- No treatment-related effects observed.
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- There were no eye lesions. The data have therefore not been tabulated.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were no differences between the groups to indicate an effect of treatment on the haematological parameters.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- The clinical chemistry profiles of the treated animals were similar to the controls.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related effects observed.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- The few microscopic findings were considered to be of agonal or incidental origin (i.e. pulmonary haemorrhage). There were no treatment-related microscopic findings.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related neoplastic histopathological findings noted.
- Other effects:
- not examined
- Details on results:
- see above
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: neoplastic
- mortality
- ophthalmological examination
- organ weights and organ / body weight ratios
- urinalysis
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: neoplastic
- mortality
- ophthalmological examination
- organ weights and organ / body weight ratios
- urinalysis
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Organ:
- other: no organ toxicity observed
- Conclusions:
- The test item did not show any mortality, clinical signs or effects on organs and food consumption. There were also neither abnormalities in the hematological and biochemical parameters nor treatment-related macroscopic and microscopic findings.
- Executive summary:
The study was performed 1991 under GLP according to OECD-guideline no. 407. Appropriate dose levels were evaluated in a DRF study. Application route was gavage, in the main study dose levels were 0, 50, 225 and 1000 mg/kg/day. Ten males and ten females were used at 0 and 1000 mg/kg/day, whereas five animals of each sex were killed at the end of treatment and the other five males and females were further observed throughout a two weeks recovery period. At 50 and 225 mg/kg/day, five animals of each sex were used per dose group. No treatment-related effects were observed, therefore the NOEL was found to be 1000 mg/kg/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Klimisch 1
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Key - Repeated dose toxicity (28d): oral
The study was performed 1991 under GLP according to OECD-guideline no. 407. Appropriate dose levels were evaluated in a DRF study. Application route was gavage, in the main study dose levels were 0, 50, 225 and 1000 mg/kg/day. Ten males and ten females were used at 0 and 1000 mg/kg/day, whereas five animals of each sex were killed at the end of treatment and the other five males and females were further observed throughout a two weeks recovery period. At 50 and 225 mg/kg/day, five animals of each sex were used per dose group. No treatment-related effects were observed, therefore the NOEL was found to be 1000 mg/kg/day.
Supporting - Repeated dose toxicity (28d): oral
In another study from 1988, performed according to OECD-guideline no. 407, EAA was administered by diet. Dose levels were 0, 50, 300 and 1000 mg/kg/day. Sixteen animals/sex/dose group were used. Neither treatment-related effects nor toxicologically significant findings were observed, therefore the NOEL and NOAEL were both found to be 1000 mg/kg/day..
Weight-of-evidence (waiver) - Repeated dose toxicity (90d): oral
The subchronic toxicity study requirement according to REACH Annex IX was waived based on a weight of evidence approach and read-across to Ethyl acetate. Based on the similar structure and properties, the substance Ethyl acetate was selected as representative model structure for read-across. Compared to EAA, the selected structure show similar physical-chemical, toxicological and ecotoxicological properties. The available data on EAA and selected model constituent revealed similar properties. Two subchronic toxicity studies with Ethyl acetate were taken into account:
1. In an inhalative guideline and GLP study on Ethyl acetate, rats exposed to concentrations of 350, 750, or 1500 ppm (1.28, 2.75, 5.49 mg/L) in air for 94 days showed no significant toxic effects. In conclusion, the NOAEL for systemic toxicity in this study is considered to be 350 ppm (1.28 mg/L) and the LOAEL 750ppm (2.75 mg/L). The LOAEL for respiratory irritant effects (nasal toxicity) is 350 ppm (1.28 mg/L).
2. In a subchronic oral toxicity of ethyl acetate was evaluated in rats by US EPA. Groups of 30 male and 30 female rats received daily doses of 0, 300, 900 or 3600 mg/kg bw/day by gavage. Some minor effects were noted in the mid and high dose groups. Based on these findings the subchronic oral NOAEL for ethyl acetate in rats is considered to be 900 mg/kg bw/day.
Weight-of-evidence (waiver) - Repeated dose toxicity (28d): inhalation
The subacute inhalation toxicity study requirement according to REACH Annex IX was waived based on a weight of evidence approach and read-across to Ethyl acetate. Based on the similar structure and properties, the substance Ethyl acetate was selected as representative model structure for read-across. Compared to EAA, the selected structure show similar physical-chemical, toxicological and ecotoxicological properties. A In a guideline and GLP study, rats exposed to concentrations of 350, 750, or 1500 ppm (1.28, 2.75, 5.49 mg/L) Ethyl acetate in air for 94 days showed no significant toxic effects. Diminished response to delivery of an alerting stimuli was noted during exposure at the 750 and 1500 ppm levels. This transient diminished response was confined to the exposure period and was attributed to acute sedative properties of ethyl acetate. Other findings at the 750 and 1500 ppm levels were limited to reduced food consumption and body weight gain, and lower levels of serum triglycerides. No other changes were seen. Some evidence of nasal mucosa degeneration was seen at 350 ppm. The NOAEL for systemic toxicity in this study is considered to be 350 ppm (1.28 mg/L) and the LOAEL 750ppm (2.75 mg/L). The LOAEL for respiratory irritant effects (nasal toxicity) is 350 ppm (1.28 mg/L).
Weight-of-evidence (waiver) - Repeated dose toxicity (28d): dermal
According to REACH Annex VIII column 1 and 2 section 8.6.1 repeated dose toxicity testing via the dermal route was waived. Instead data on repeated dose toxicity testing (28d) via the oral route is presented. A NOAEL long-term, dermal of 1000 mg/kg bw/day was calculated from the NOAEL long-term, oral of 1000 mg/kg bw/day, assuming 100 % resorption through the skin. The results of laboratory animal studies with Methyl acetoacetate show low acute dermal toxicity. In the 28 - days repeated dose study via oral gavage administration does not exacerbate systemic toxicity effects, which suggest bioavailability is low, thereby there is low toxicity potential. This intrinsic property/toxicity potential can be extrapolated to repeated dermal route administration.
Justification for selection of
repeated dose toxicity via oral route - systemic effects endpoint:
Guideline study; Klimisch 1
Justification for classification or non-classification
Based on the data available the substance is not classified or labeled according to Directive 67/548/EEC (DSD) or Regulation 1272/2008/EC (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.